Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $67,872 - $80,990
-1,400 Reduced 25.69%
4,050 $207,000
Q2 2023

Aug 02, 2023

SELL
$63.71 - $70.74 $95,565 - $106,109
-1,500 Reduced 21.58%
5,450 $348,000
Q4 2022

Jan 23, 2023

SELL
$68.48 - $81.09 $13,011 - $15,407
-190 Reduced 2.66%
6,950 $0
Q3 2022

Oct 19, 2022

SELL
$0.13 - $76.84 $1 - $768
-10 Reduced 0.14%
7,140 $508,000
Q2 2022

Jul 26, 2022

BUY
$72.62 - $79.98 $63,542 - $69,982
875 Added 13.94%
7,150 $551,000
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $58,406 - $70,034
950 Added 17.84%
6,275 $458,000
Q4 2021

Feb 02, 2022

SELL
$53.63 - $62.52 $4,558 - $5,314
-85 Reduced 1.57%
5,325 $332,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $5,029 - $5,891
85 Added 1.6%
5,410 $320,000
Q2 2021

Aug 10, 2021

BUY
$61.91 - $67.42 $91,007 - $99,107
1,470 Added 38.13%
5,325 $356,000
Q4 2020

May 07, 2021

BUY
$57.74 - $65.43 $201,685 - $228,546
3,493 Added 964.92%
3,855 $239,000
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $233,731 - $264,860
-4,048 Reduced 91.79%
362 $23,000
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $17,516 - $19,410
305 Added 7.43%
4,410 $266,000
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $24,669 - $28,840
-450 Reduced 9.88%
4,105 $241,000
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $67,280 - $97,773
1,450 Added 46.7%
4,555 $254,000
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $152,797 - $199,309
3,105 New
3,105 $199,000
Q1 2019

May 07, 2019

SELL
$45.12 - $53.8 $112,123 - $133,693
-2,485 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $121,168 - $157,126
2,485 New
2,485 $129,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Meridian Wealth Advisors, LLC Portfolio

Follow Meridian Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meridian Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Meridian Wealth Advisors, LLC with notifications on news.